Dr. Margolin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Genzyme Corporation
500 Kendall Street, GC 5-191
Cambridge, MA 02142Phone+1 617-768-8007Fax+1 617-768-8093- Is this information wrong?
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1991 - 1994
- Graduate HospitalInternship, Internal Medicine, 1990 - 1991
- Perelman School of Medicine at the University of PennsylvaniaClass of 1990
Certifications & Licensure
- MA State Medical License 1994 - 2015
Publications & Presentations
PubMed
- 1 citationsEndocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.Colin M Dayan, Beatriz Lecumberri, Ilaria Muller, Sashiananthan Ganesananthan, Samuel F Hunter, Krzysztof W Selmaj, Hans-Peter Hartung, Eva K Havrdova, Christopher C L...> ;Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2023 Jan 3
- 9 citationsMismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose...Pejman Sehatpour, Daniel C. Javitt, Heloise M. De Baun, Marlene Carlson, Anna Beloborodova, David H. Margolin, Mark Carlton, Nicola Brice, Joshua T. Kantrowitz> ;Neuropsychopharmacology. 2021 Oct 20
- 26 citationsEfficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial:Alasdair Coles, Douglas L. Arnold, Ann D Bass, Aaron Boster, D Alastair S Compston, Oscar Fernandez, Eva Havrdova, Kunio Nakamura, Anthony Traboulsee, Tjalf Ziemssen, ...> ;Therapeutic Advances in Neurological Disorders. 2021 Apr 23
- Join now to see all
Press Mentions
- Cerevance Initiates Phase 2 Trial of CVN424 for Parkinson’s DiseaseDecember 4th, 2019
- Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424April 30th, 2019
Grant Support
- B Cell Responses To SHIVNational Institute Of Allergy And Infectious Diseases1999–2003
- Cloning Hiv-1-Neutralizing Fabs From LN Tissue SectionsNational Institute Of Allergy And Infectious Diseases1999–2000
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: